293 related articles for article (PubMed ID: 21745317)
1. Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
Afzelius P; Bazeghi N; Bie P; Bendtsen F; Vestbo J; Møller S
Liver Int; 2011 Oct; 31(9):1381-7. PubMed ID: 21745317
[TBL] [Abstract][Full Text] [Related]
2. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation.
Arkenau HT; Stichtenoth DO; Frölich JC; Manns MP; Böker KH
Z Gastroenterol; 2002 Nov; 40(11):907-13. PubMed ID: 12436367
[TBL] [Abstract][Full Text] [Related]
3. Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume.
Møller S; Bendtsen F; Henriksen JH
Scand J Gastroenterol; 2006 Apr; 41(4):451-8. PubMed ID: 16635914
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.
Genesca J; Gonzalez A; Segura R; Catalan R; Marti R; Varela E; Cadelina G; Martinez M; Lopez-Talavera JC; Esteban R; Groszmann RJ; Guardia J
Am J Gastroenterol; 1999 Jan; 94(1):169-77. PubMed ID: 9934750
[TBL] [Abstract][Full Text] [Related]
5. Elevated plasma levels of urotensin II do not correlate with systemic haemodynamics in patients with cirrhosis.
Romanelli RG; Laffi G; Vizzutti F; Del Bene R; Marra F; Caini P; Guerra CT; La Villa G; Barletta G
Dig Liver Dis; 2011 Apr; 43(4):314-8. PubMed ID: 20943446
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension.
La Mura V; Reverter JC; Flores-Arroyo A; Raffa S; Reverter E; Seijo S; Abraldes JG; Bosch J; García-Pagán JC
Gut; 2011 Aug; 60(8):1133-8. PubMed ID: 21427197
[TBL] [Abstract][Full Text] [Related]
7. The molecules: mechanisms of arterial vasodilatation observed in the splanchnic and systemic circulation in portal hypertension.
Iwakiri Y
J Clin Gastroenterol; 2007; 41 Suppl 3():S288-94. PubMed ID: 17975478
[TBL] [Abstract][Full Text] [Related]
8. Splanchnic and systemic haemodynamic response to volume changes in patients with cirrhosis and portal hypertension.
Vlavianos P; Mac Mathuna P; Williams R; Westaby D
Clin Sci (Lond); 1999 May; 96(5):475-81. PubMed ID: 10209079
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
[TBL] [Abstract][Full Text] [Related]
11. Underlying mechanism of portal hypertensive gastropathy in cirrhosis: a hemodynamic and morphological approach.
Curvêlo LA; Brabosa W; Rhor R; Lanzoni V; Parise ER; Ferrari AP; Kondo M
J Gastroenterol Hepatol; 2009 Sep; 24(9):1541-6. PubMed ID: 19743998
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
[TBL] [Abstract][Full Text] [Related]
13. Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension.
Malinovschi A; Henrohn D; Eriksson A; Lundberg JO; Alving K; Wikström G
Eur J Clin Invest; 2011 Aug; 41(8):889-97. PubMed ID: 21554268
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis.
Mortensen C; Andersen O; Krag A; Bendtsen F; Møller S
Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):619-26. PubMed ID: 22441510
[TBL] [Abstract][Full Text] [Related]
15. Haemodynamic changes in portal hypertension: new insights in the pathogenesis and clinical implications.
Michielsen PP; Pelckmans PA
Acta Gastroenterol Belg; 1994; 57(2):194-205. PubMed ID: 8053307
[TBL] [Abstract][Full Text] [Related]
16. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.
Bolognesi M; Di Pascoli M; Verardo A; Gatta A
World J Gastroenterol; 2014 Mar; 20(10):2555-63. PubMed ID: 24627591
[TBL] [Abstract][Full Text] [Related]
17. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy: a study of 254 cirrhotics.
Kumar A; Mishra SR; Sharma P; Sharma BC; Sarin SK
J Clin Gastroenterol; 2010 Apr; 44(4):294-300. PubMed ID: 19730114
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic alterations in liver cirrhosis.
La Villa G; Gentilini P
Mol Aspects Med; 2008; 29(1-2):112-8. PubMed ID: 18177931
[TBL] [Abstract][Full Text] [Related]
19. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis.
Rolla G; Brussino L; Colagrande P; Dutto L; Polizzi S; Scappaticci E; Bergerone S; Morello M; Marzano A; Martinasso G; Salizzoni M; Bucca C
Hepatology; 1997 Oct; 26(4):842-7. PubMed ID: 9328302
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the short-term effects of mepindolol and propranolol on splanchnic and systemic haemodynamics in patients with cirrhosis.
Braillon A; Calès P; Lebrec D
Int J Clin Pharmacol Res; 1985; 5(4):223-8. PubMed ID: 4055165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
